Teplizumab therapy for type 1 diabetes

Bibliography

• Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 1986;35:855-60
   PubMed Web of Science ®Google Scholar
• Lampeter EF, McCann SR, Kolb H. Transfer of diabetes type 1 by bone-marrow transplantation. Lancet 1998;351:568-9
   PubMed Web of Science ®Google Scholar
• Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-85
   PubMed Web of Science ®Google Scholar
• Lindley S, Dayan CM, Bishop A, Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005;54:92-9
   PubMed Web of Science ®Google Scholar
• Phillips B, Giannoukakis N, Trucco M. Dendritic cell-based therapy in type 1 diabetes mellitus. Expert Rev Clin Immunol 2009;5:325-39
   PubMed Web of Science ®Google Scholar
• Martin AP, Rankin S, Pitchford S, Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes. Diabetes 2008;57:3025-33
   PubMed Web of Science ®Google Scholar
• Yang LJ. Big mac attack: does it play a direct role for monocytes/macrophages in type 1 diabetes? Diabetes 2008;57:2922-3
   PubMed Web of Science ®Google Scholar
• Yang M, Charlton B, Gautam AM. Development of insulitis and diabetes in B cell-deficient NOD mice. J Autoimmun 1997, 10:257-60
   PubMed Web of Science ®Google Scholar
• Martin S, Wolf-Eichbaum D, Duinkerken G, Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001;345:1036-40
   PubMed Web of Science ®Google Scholar
• Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev 2005;204:232-49
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005;28:1068-76
   PubMed Web of Science ®Google Scholar
• Skyler JS. Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 2007;81:768-71
   PubMed Web of Science ®Google Scholar
• Martin S, Pawlowski B, Greulich B, Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 1992;15:66-74
   PubMed Web of Science ®Google Scholar
• Pasquali L, Fan Y, Trucco M, Rehabilitation of adaptive immunity and regeneration of beta cells. Trends Biotechnol 2006;24:516-22
   PubMed Web of Science ®Google Scholar
• Cernea S, Pozzilli P. New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. Diabet Med 2008;25:1259-67
   PubMed Web of Science ®Google Scholar
• Li L, Yi Z, Tisch R, Immunotherapy of type 1 diabetes. Arch Immunol Ther Exp (Warsz) 2008;56:227-36
   PubMed Web of Science ®Google Scholar
• Herold KC. Achieving antigen-specific immune regulation. J Clin Invest 2004;113:346-9
   PubMed Web of Science ®Google Scholar
• O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004;10:801-5
   PubMed Web of Science ®Google Scholar
• Lehmann PV, Forsthuber T, Miller A, Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-7
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hjorth M, GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-20
   PubMed Web of Science ®Google Scholar
• Gottlieb P, Eisenbarth GS, Kipnes M. et al. Interim results of a phase I/II clinical trial of a DNA plasmid vaccine (BHT-3021) for type 1 diabetes. EASD 2008, Rome, Italy
   Google Scholar
• Bougneres PF, Landais P, Boisson C, Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990;39:1264-72
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS, Srikanta S, Jackson R, Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985;2:271-6
   PubMedGoogle Scholar
• Harrison LC, Colman PG, Dean B, Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985;34:1306-8
   PubMed Web of Science ®Google Scholar
• Parving HH, Tarnow L, Nielsen FS, Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999, 22:478-83
   PubMed Web of Science ®Google Scholar
• Silverstein J, Maclaren N, Riley W, Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319:599-604
   PubMed Web of Science ®Google Scholar
• Stiller CR, Dupre J, Gent M, Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984;223:1362-7
   PubMed Web of Science ®Google Scholar
• A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 1985;313:337-42
   PubMed Web of Science ®Google Scholar
• Cosimi AB, Colvin RB, Burton RC, Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981;305:308-14
   PubMed Web of Science ®Google Scholar
• Kung P, Goldstein G, Reinherz EL, Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979;206:347-9
   PubMed Web of Science ®Google Scholar
• Vigeral P, Chkoff N, Chatenoud L, Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 1986;41:730-3
   PubMed Web of Science ®Google Scholar
• Davis MM, Chien YH. In: Paul WE, editor, T Cell antigen receptors. Fundamental immunology. 6th edition. 1999. p. 341-66
   Google Scholar
• Thistlethwaite JR, Jr., Stuart JK, Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988, 11:112-9
   PubMed Web of Science ®Google Scholar
• Abramowicz D, Schandene L, Goldman M, Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989;47:606-8
   PubMed Web of Science ®Google Scholar
• Alegre M, Vandenabeele P, Flamand V, Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur J Immunol 1990;20:707-10
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Legendre C, Ferran C, Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome–dosage and kinetics prerequisites. Transplantation 1991;51:334-8
   PubMed Web of Science ®Google Scholar
• Ferran C, Sheehan K, Dy M, Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990;20:509-15
   PubMed Web of Science ®Google Scholar
• Hirsch R, Gress RE, Pluznik DH, Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989;142:737-43
   PubMed Web of Science ®Google Scholar
• Alegre ML, Peterson LJ, Xu D, A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994;57:1537-43
   PubMed Web of Science ®Google Scholar
• Bolt S, Routledge E, Lloyd I, The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-11
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Thervet E, Primo J, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-7
   PubMed Web of Science ®Google Scholar
• Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003;3:123-32
   PubMed Web of Science ®Google Scholar
• Chatenoud L. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr Opin Organ Transplant 2009;14:351-6
   PubMed Web of Science ®Google Scholar
• Herold KC, Bluestone JA, Montag AG, Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41:385-91
   PubMed Web of Science ®Google Scholar
• Hughes C, Wolos JA, Giannini EH, Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J Immunol 1994;153:3319-25
   PubMed Web of Science ®Google Scholar
• Johnson BD, McCabe C, Hanke CA, Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J Immunol 1995;154:5542-54
   PubMed Web of Science ®Google Scholar
• Hirsch R, Bluestone JA, DeNenno L, Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990;49:1117-23
   PubMed Web of Science ®Google Scholar
• Parlevliet KJ, Ten BI, Yong SL, In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994;93:2519-25
   PubMedGoogle Scholar
• van Lier RA, Boot JH, de Groot ER, Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol 1987;17:1599-604
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Reshaping human antibodies for therapy. Nature 1988;332:323-7
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-54
   PubMed Web of Science ®Google Scholar
• Belghith M, Bluestone JA, Barriot S, TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-8
   PubMed Web of Science ®Google Scholar
• Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003;3:123-32
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells – they're back and critical for regulation of autoimmunity! Immunol. Rev 2001;182:149-63
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest 2003;112:1310-2
   PubMed Web of Science ®Google Scholar
• Walker MR, Kasprowicz DJ, Gersuk VH, Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25 - T cells. J Clin Invest 2003;112:1437-43
   PubMed Web of Science ®Google Scholar
• Bisikirska B, Colgan J, Luban J, TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005;115:2904-13
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U, A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-9
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman S, Greenbaum C, Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132:166-73
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608
   PubMed Web of Science ®Google Scholar
• Kong F, Chen CH, Cooper MD. Thymic function can be accurately monitored by the level of recent T cell emigrants in the circulation. Immunity 1998, 8:97-104
   PubMed Web of Science ®Google Scholar
• Woodle ES, Xu D, Zivin RA, Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999, 68:608-16
   PubMed Web of Science ®Google Scholar
• Hering BJ, Kandaswamy R, Harmon JV. Insulin independence after single-donor islet transplantation in type 1 diabetes with hOKT3y1(Ala-Ala), sirolimus and tacrolimus therapy [abstract 190]. Am J Transplant 2001;(Suppl 1):180
   Google Scholar
• Hering BJ, Kandaswamy R, Harmon JV, Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am.J Transplant 2004;4:390-401
   PubMed Web of Science ®Google Scholar
• Skyler JS, Greenbaum CJ, Lachin JM, Type 1 Diabetes TrialNet–an international collaborative clinical trials network. Ann N Y Acad Sci 2008;1150:14-24
   PubMed Web of Science ®Google Scholar
• Utset TO, Auger JA, Peace D, Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 2002;29:1907-13
   PubMed Web of Science ®Google Scholar
• Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998;128:517-23
   PubMed Web of Science ®Google Scholar
• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9
   PubMed Web of Science ®Google Scholar